AIM: We investigated the influence of hormone replacement therapy (HRT) use on the risk of meningioma in a population-based setting. METHODS: We conducted a nationwide case-control study in Denmark based on population-based administrative and health registries. The study included all female patients aged 55-84 years with a first time diagnosis of meningioma during 2000-2009. The cases were matched on birth year with female population controls. Ever use of HRT since 1995 was defined as ≥2 HRT prescriptions and categorised according to HRT type (oestrogen only, combined oestrogen-progestagen, and progestagen only) and cumulated duration of use (<1, ≥1 to <5, ≥5 to <10, ≥10 years). We used conditional logistic regression to compute odds ratios (ORs), with 95% confidence intervals (CIs), for meningioma associated with HRT use, and adjusting for potential confounders. RESULTS: We identified 924 cases and 6122 controls. Ever use of HRT was associated with an increased risk of meningioma (OR, 1.3; 95%CI, 1.1-1.5) compared with non-use (0-1 prescriptions). The risk increased with increasing duration of HRT use, reaching an OR of 1.7 (95% CI, 1.2-2.3) after more than 10 years of use. The risk of meningioma associated with long-term (≥10 years) HRT use was most pronounced for combined oestrogen-progestagen therapy (OR, 2.2; 95% CI, 1.4-3.3), especially when this regimen constituted the sole HRT therapy (OR, 2.7; 95% CI, 0.9-7.5), although the latter estimate was based on small numbers. CONCLUSIONS: Long-term HRT use, particularly of combined oestrogen-progestagen therapy, may increase the risk of meningioma.
AIM: We investigated the influence of hormone replacement therapy (HRT) use on the risk of meningioma in a population-based setting. METHODS: We conducted a nationwide case-control study in Denmark based on population-based administrative and health registries. The study included all female patients aged 55-84 years with a first time diagnosis of meningioma during 2000-2009. The cases were matched on birth year with female population controls. Ever use of HRT since 1995 was defined as ≥2 HRT prescriptions and categorised according to HRT type (oestrogen only, combined oestrogen-progestagen, and progestagen only) and cumulated duration of use (<1, ≥1 to <5, ≥5 to <10, ≥10 years). We used conditional logistic regression to compute odds ratios (ORs), with 95% confidence intervals (CIs), for meningioma associated with HRT use, and adjusting for potential confounders. RESULTS: We identified 924 cases and 6122 controls. Ever use of HRT was associated with an increased risk of meningioma (OR, 1.3; 95%CI, 1.1-1.5) compared with non-use (0-1 prescriptions). The risk increased with increasing duration of HRT use, reaching an OR of 1.7 (95% CI, 1.2-2.3) after more than 10 years of use. The risk of meningioma associated with long-term (≥10 years) HRT use was most pronounced for combined oestrogen-progestagen therapy (OR, 2.2; 95% CI, 1.4-3.3), especially when this regimen constituted the sole HRT therapy (OR, 2.7; 95% CI, 0.9-7.5), although the latter estimate was based on small numbers. CONCLUSIONS: Long-term HRT use, particularly of combined oestrogen-progestagen therapy, may increase the risk of meningioma.
Authors: Ivo S Muskens; Anna H Wu; Jacqueline Porcel; Iona Cheng; Loïc Le Marchand; Joseph L Wiemels; Veronica Wendy Setiawan Journal: Neuro Oncol Date: 2019-03-18 Impact factor: 12.300
Authors: John Varlotto; John Flickinger; Martin T Pavelic; Charles S Specht; Jonas M Sheehan; Dana T Timek; Michael J Glantz; Steven Sogge; Christopher Dimaio; Richard Moser; Shakeeb Yunus; Thomas J Fitzgerald; Urvashi Upadhyay; Paul Rava; Matthew Tangel; Aaron Yao; Sangam Kanekar Journal: Oncotarget Date: 2015-11-10
Authors: Li-Nien Chien; Haley Gittleman; Quinn T Ostrom; Kuo-Sheng Hung; Andrew E Sloan; Yi-Chen Hsieh; Carol Kruchko; Lisa R Rogers; Ye-Fan Glavin Wang; Hung-Yi Chiou; Jill S Barnholtz-Sloan Journal: Front Public Health Date: 2016-07-21
Authors: Hannah Takahashi; Alex J Cornish; Amit Sud; Philip J Law; Linden Disney-Hogg; Lisa Calvocoressi; Lingeng Lu; Helen M Hansen; Ivan Smirnov; Kyle M Walsh; Johannes Schramm; Per Hoffmann; Markus M Nöthen; Karl-Heinz Jöckel; Joellen M Schildkraut; Matthias Simon; Melissa Bondy; Margaret Wrensch; Joseph L Wiemels; Elizabeth B Claus; Clare Turnbull; Richard S Houlston Journal: Sci Rep Date: 2019-01-22 Impact factor: 4.379
Authors: Agus Supartoto; Muhammad Bayu Sasongko; Datu Respatika; Indra Tri Mahayana; Suhardjo Pawiroranu; Hari Kusnanto; Dhimas Hari Sakti; Prima Sugesty Nurlaila; Didik Setyo Heriyanto; Sofia Mubarika Haryana Journal: Front Oncol Date: 2019-01-09 Impact factor: 6.244